Fibroblast growth factors (a family of 22 distinct polypeptides) and their transmembrane tyrosine kinase receptors (FGFR1-FGFR4) play a critical role in several cancers.1 Overexpression, gain-of-function mutations and gene fusions are the main aberrant alterations leading to oncogenic function of FGFR.2 Lucitanib and dovitinib were the first nonselective FGFR tyrosine kinase inhibitors (TKIs) investigated in advanced cancers.